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Background: The IMMEDIATE Trial of emergency medical service use of intravenous glucose–insulin–potassium
(GIK) very early in acute coronary syndromes (ACS) showed beneﬁt for the composite outcome of cardiac arrest
or in-hospital mortality.
Objectives: This analysis of IMMEDIATE Trial data sought to develop a predictive model to help clinicians identify
patients at highest risk for this outcome and most likely to beneﬁt from GIK.
Methods:Multivariable logistic regression was used to develop a predictive model for the composite endpoint
cardiac arrest or in-hospital mortality using the 460 participants in the placebo arm of the IMMEDIATE Trial.
Results: Theﬁnalmodel had four variables: advanced age, low systolic blood pressure, ST elevation in thepresent-
ing electrocardiogram, and duration of time since ischemic symptom onset. Predictive performance was good,
with a C statistic of 0.75, as was its calibration. Stratifying patients into three risk categories based on themodel's
predictions, there was an absolute risk reduction of 8.6% with GIK in the high-risk tertile, corresponding to 12
patients needed to treat to prevent one bad outcome. The corresponding values for the low-risk tertile were
0.8% and 125, respectively.
Conclusions: The multivariable predictivemodel developed identiﬁed patients with very early ACS at high risk of
cardiac arrest or death. Using this model could assist treating those with greatest potential beneﬁt from GIK.
© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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Studies in animals suggest that intravenous glucose–insulin–
potassium (GIK), when administered very early during the course of
cardiac ischemia, reduces ischemia-induced arrhythmias andmyocardi-
al injury [1]. Clinical trials in humans, however, have produced conﬂict-
ing results [2–5] which have been postulated to be due to the variable
delay in the administration of GIK after the onset of ischemia. Supporting
the importance of very early identiﬁcation of suitable patients and
treatment, the IMMEDIATE (ImmediateMyocardialMetabolic Enhance-
ment During Initial Assessment and Treatment in Emergency care)
Trial, which studied very early administration of GIK to patients with
an acute coronary syndrome (ACS) by emergency medical service
(EMS), showed reduction in the composite endpoint of cardiac arrest
or in-hospital mortality in the study group, thereby supporting the
importance of prompt identiﬁcation of these patients [6].C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ous coronary intervention (PCI), there have been signiﬁcant reductions
in mortality. To maximize this impact, there is a need to identify
patients with suspected ACS who are at high risk for cardiac arrest or
death very early in their clinical course, such as during initial evaluation
by EMS. This identiﬁcation remains challenging, however. Among pa-
tients presenting with chest pain or other symptoms suggesting ACS,
only about a quarter truly have ACS, and among those with ACS, rapid
identiﬁcation of those at high risk is crucial in order to provide prompt
treatment and allocation of valuable attention and resources [7].
To address this need, using data from the IMMEDIATE Trial, we used
logistic regression to develop a predictive model to stratify the risk of
cardiac arrest or death among patients presenting with suspected ACS.
We then examined the degree of GIK's treatment effect across risk
groups deﬁned by the predictive model.
2. Methods
2.1. Dataset
This study used data from the IMMEDIATE Trial. Details of the study
protocol and inclusion and exclusion criteria have been published else-
where [6,8].It was a randomized, placebo-controlled, double-blind,
multicenter clinical effectiveness trial conducted across the United
States that assessed the effect of intravenous GIK infusion initiated by
EMS in the out-of-hospital setting for patients with suspected ACS. Of
its 871 randomized participants; for the development of the predictive
model,we used only data from the control (placebo) group, to represent
the clinical course of ACS uninﬂuenced by GIK.
2.2. The IMMEDIATE Trial inclusion and exclusion criteria
Screened patients included those transported by EMS who were
30 years of age or older and had an out-of-hospital electrocardiogram
(ECG) done for symptoms suggestive of ACS. To be included, a patient's
out-of-hospital ECG had to meet at least one of the following criteria: a
75% or higher prediction of ACS by the acute ischemia time insensitive
predictive instrument (ACI-TIPI) [7], the generation by the thrombolytic
predictive instrument (TPI) of a statement recognizing ST elevation
myocardial infarction (STEMI) [7], or a judgment by the paramedic
that the ECG showed deﬁnite STEMI using local standards. Excluded
were patients who had a language barrier, impaired reasoning, were
prisoners, pregnant, or had rales suggesting heart failure. Informed con-
sentwas obtained from each patient and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki as reﬂected in
a priori approval by the institution's human research committee.
2.3. Presenting clinical variables
For analyses, our main independent variables were demographic,
clinical and electrocardiographic. These included age, sex, body mass
index, time of initiation of study drug (GIK or placebo) after the onset
of ischemic symptoms, vital signs (pulse, and systolic and diastolic
blood pressures) obtained out-of-hospital and in the emergency depart-
ment (ED), medical history of coronary artery disease (myocardial in-
farction, coronary artery revascularization, heart failure, and stroke),
cardiovascular risk factors (diabetes mellitus, hypertension, and hyper-
lipidemia), history of hemodialysis, previous use of aspirin, and treat-
ment with beta blocker. Electrocardiographic variables included ST
elevation, PR interval, QRS duration, corrected QT interval (QTc), and
the axes of the P, T, and QRS waves. We also used the probability of
ACS computed by the ACI-TIPI [7,9] and for the QTc variable, categories
previously developed in a cardiac arrest model [10], and for heart rate
and blood pressure, variables previously used in predictive models of
cardiac arrest and in-hospital mortality [11–13].2.4. Clinical outcome to be predicted
The outcome of interest was the composite of cardiac arrest or
in-hospital mortality, as adjudicated for the IMMEDIATE Trial [6,8].
2.5. Development of predictive model
Using data from the IMMEDIATE Trial control participants, we com-
pared baseline characteristics of those with and without the cardiac
arrest or mortality composite outcome. Between group differences
were assessed by logistic regression based on demographic, clinical,
and ECG data. Variables that were signiﬁcant at p b 0.01 were included
in the multivariable model building process to identify patients at
highest risk for the composite outcome (who thereby might beneﬁt
most by early administration of GIK). Collinearitywas tested by examin-
ing the variance inﬂation factor (vif); if its square root was more than
two, collinearity was suspected and the variable with lowest p value
was used in further analyses.
Stepwise multivariable logistic regression analysis was performed
using the most promising variables from the univariate analyses. Clini-
cal meaningfulness and the Akaike Information Criteria (AIC) were
used in variable selection, resulting in the model with four variables
described below.
The ﬁnal model was tested for predictive discrimination by C statis-
tic (the equivalent of the area under the receiver-operating characteris-
tic [ROC] curve). Predicted values from the ﬁnal model were calculated
for all patients (GIK and placebo treated), which were used to stratify
patients into tertiles of risk. The observed event rates in each risk cate-
gory were calculated and compared between the GIK and placebo
groups. We checked for interactions of GIK with different covariates in
the model and also with the different risk categories. Finally, we evalu-
ated the clinical characteristics of patients in the highest risk group for
consideration for early GIK therapy.
3. Results
Table 1 shows the baseline characteristics of the study sample and
rates of cardiac arrest or in-hospital mortality.
Of the 871 trial participants (411 given GIK and 460 given placebo),
58 had an out- or in-hospital cardiac arrest or died during the index hos-
pitalization. Forty occurred in the control group (29 cardiac arrests, 23
with in-hospital mortality, and 12 with both), and 18 in the GIK group
(15 cardiac arrests, 13 with in-hospital mortality, and 10 with both).
To construct the risk predictive model of baseline risk, we used the
data from the placebo group (n = 460). As in Table 1, when compared
to the participants without any events, those with one of these events
were slightly older andmore likelywomen, presented later (but not sig-
niﬁcantly), had systolic blood pressures that were about 10 mm Hg
lower and pulse rates about 10 beats per minute higher, had more fre-
quent histories of previous coronary artery disease, more often had ST
elevation on their presenting ECG, and had higher ACI-TIPI probabilities
of having ACS. These differences are consistent with those who have
cardiac arrest, are ofmore advanced age, have lower systolic blood pres-
sure, tachycardia, history of coronary artery disease, ST elevation on
presentation, and higher ACI-TIPI score, These were considered appro-
priate variables for the predictive model.
Among 34 candidate variables, 11 were statistically signiﬁcant and
one borderline signiﬁcant. Among demographic variables, age was sig-
niﬁcant and gender was not. Neither traditional cardiovascular risk fac-
tors, nor history of coronary artery disease, heart failure, stroke, use of
aspirin, or beta blocker were signiﬁcantly related to the outcome. Fur-
ther characterization of age using restricted cubic spline demonstrated
a nonlinear relationship of age with the outcome of interest. Two
nodes were noted at 60 and 85 years of age. Graphically there was no
obvious difference in the outcome rates below 60 and above 85 years
of age. Thus, based on the data the age variable was truncated at 60
Table 1
Baseline characteristics of participants treated with placebo stratiﬁed by outcome groups (N= 460).
Characteristics Participants with cardiac arrest
or in-hospital mortality
N = 40, n = (#) when n b N
Participants without cardiac
arrest or in-hospital mortality
N = 420, n = (#) when n b N
p value
(logistic regression
Chi square)
Age (mean ± SD, years) 68.4 ± 13.74 62.84 ± 14.11 0.019
Gender, % male 65% 70% 0.512
BMI 28.48 ± 5.9 (n = 27) 29.17 ± 7.04 (n = 385) 0.614
Time from onset of symptoms to treatment (minutes)
Mean ± SD 140.2 ± 192.63 (n = 32) 154.2 ± 184.45 (n = 356) 0.684
Median (IQR) 54.5 (43.0 to 151.8) 85 (51.75 to 166.75)
Vital signs (mean± SD, years)
Out-of-hospital
Systolic BP (mm Hg) 126.2 ± 34.66 145.1 ± 34.64 (n = 417) b0.001
Diastolic BP (mm Hg) 78.66 ± 22.14 (n = 38) 85.55 ± 25.27 (n = 413) 0.103
Pulse rate (beats/m) 86.05 ± 27.34 86.65 ± 25.43 (n = 417) 0.887
Respiration rate/m 20.1 ± 5.52 (n = 39) 19.41 ± 4.42 (n = 403) 0.346
In emergency department
Systolic BP (mm Hg) 122.8 ± 26.87 138.4 ± 27.2 b0.001
Diastolic BP (mm Hg) 71.13 ± 22.77 (n = 39) 81.46 ± 17.62 (n = 418) 0.001
Pulse rate (beats/m) 90.58 ± 23.94 83.08 ± 22.62 0.048
Respiration rate/min 19.41 ± 4.10 (n = 39) 19.06 ± 4.07 (n = 412) 0.605
Medical history, % (n)
MI 40.0% (16) 34.1% (143) 0.45
CABG 22.5% (9) 13.3% (56) 0.117
PCI 42.5% (17) 25.7% (108) 0.025
CHF 17.5% (7) 16.7% (70) 0.893
Stroke 7.5% (3) 8.6% (36) 0.816
DM 30.0% (12) 26.0% (109) 0.579
Hypertension 72.5% (29) 66.9% (281) 0.472
Hyperlipidemia 47.5% (19) 50.0% (210) 0.763
Previous aspirin 60.0% (24) 50.24% (211) 0.24
Previous beta blocker 37.5% (15) 39.05% (164) 0.848
Initial in-hospital laboratory values
Glucose (mg/dl) 231.8 ± 137.6 (n = 39) 164.1 ± 89.33 (n = 415) 0.004
Potassium (mEq/L) 4.09 ± 0.81 (n = 39) 3.93 ± 0.53 (n = 410) 0.094
Out-of-hospital ECG
ST segment elevation 70.0% (28) 39.52% (166) b0.001
ACI-TIPI score (mean ± SD) 85.26 ± 9.33 (n = 25) 76.09 ± 21.22 (n = 314) 0.011
PR interval (ms) 138.7 ± 84.45 (n = 25) 135.8 ± 74.28 (n = 314) 0.852
QTc duration (ms) 430.3 ± 31.45 (n = 25) 431.3 ± 74.28 (n = 314) 0.937
QRS axis (degrees) 43.68 ± 45.47 (n = 25) 24.92 ± 57.40 (n = 314) 0.112
T wave axis (degrees) 80.6 ± 81.89 (n = 25) 73.3 ± 68.92 (n = 314) 0.614
P wave axis (degrees) 58.24 ± 53.60 (n = 25) 50.9 ± 47.17 (n = 314) 0.458
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pattern andwas treated as a continuous variable. This resulted in a small
degree of further improvement in model performance.
Univariate analyses of systolic blood pressure suggested a non-linear
relationship; systolic blood pressure less than 105mmHgwas adverse-
ly related to the outcome. Therefore the systolic blood pressure variable
was dichotomized at 105 mm Hg.
Time from onset of chest pain to presentation as a continuous linear
variable was not predictive of the outcome. Based on clinical consider-
ations and numbers of participants, the duration of symptoms was di-
vided into two categories: early (within 1 h), and late (beyond 1 h).
The odds of the outcome were four times higher in those treated
(with placebo) within an hour of symptom onset compared to those
presenting late, consistent with other analyses of cardiac arrest in
acute infarction having a sharp drop-off after 1 h [13]. As many of the
interventional trials used two or 3 h as the duration of symptoms at pre-
sentation, a sensitivity analysis was performed to look for any differ-
ence. However, no signiﬁcant difference was found in its predictive
value when two or 3 h were used as the cutoff points in place of 1 h.
Previous investigators [10] have suggested a predictive role of QTc as
a function of time since onset of symptoms suggestive of ACS, reﬂects
myocardial injury and prolongation of QTc (and QT dispersion) [14,
15], potentially promoting ventricular arrhythmias and cardiac arrest.Although univariate analyses did not demonstrate signiﬁcant predictive
value of QTc or duration of symptoms, a composite variable of QTc with
duration of chest pain since onset was created as described in the liter-
ature [10]. This variable was tested in the multivariable model, and no
improvement in model performance was found.
We used both heart rate and systolic blood pressure to account for
the hemodynamic state of the patient, including a composite variable
found signiﬁcant for predicting mortality from ACS in another study
[14]. No improvement was noted in the model as measured by C
statistic.
In the out-of-hospital setting, systolic blood pressure was found to
be a signiﬁcant covariate and respiratory rate was of borderline signiﬁ-
cance. When vital signs recorded in the ED were analyzed, systolic and
diastolic blood pressures, heart rate, and respiratory rate were signiﬁ-
cantly related to the outcome. Higher serum potassium level had a sig-
niﬁcant protective role, whereas glucose and C-reactive protein (CRP)
levels did not show predictive signiﬁcance. However, blood tests were
judged unattractive as presenting clinical variables and were not used
for the predictive model. Among ECG-based variables, ST elevation on
the presenting ECG and a high ACI-TIPI scorewere signiﬁcant predictors
in the univariate models tested.
Based on all these considerations, stepwisemultivariable logistic re-
gression selection resulted in a ﬁnal model with four variables: age
Table 3
Calibration in the developmental data (placebo group of the IMMEDIATE Trial).
Risk
tertile
Total Mean predicted
risk
Predicted number
of eventsa
Observed number
of events
Low 153 2.3% 3.6 5
Moderate 152 6.2% 9.4 8
High 152 17.8% 27.0 27
a Event = cardiac arrest or in-hospital death.
40 M. Ray et al. / IJC Heart & Vasculature 9 (2015) 37–42(truncated at 60 and 85 years), systolic blood pressure (dichotomized at
105mmHg), presence of ST elevation in the initial ECG, and duration of
time from symptom onset until initiation of treatment (dichotomized at
1 h), in Table 2.
Fig. 1 in the Appendix shows the ROC curve for the model's predic-
tions; good discrimination is reﬂected by the C statistic (ROC area) of
0.75, and calibration, in Table 3, shows good agreement of predicted
to actual outcomes. The C statistic for the GIK group was 0.73 with a
95% conﬁdence interval of 0.61–0.85. Fig. 2 in the Appendix shows the
ROC curve for the treatment group while the adjoining Table 1 and
Fig. 3 show the calibration.
Based on the ﬁnal model, we calculated a predicted risk score as a
continuous 0–100% variable. For potential clinical use, tertiles of risk
categories were created and event rates calculated for each risk catego-
ry. Among the placebo group participants, the event ratewas 3.4% in the
low risk category, 5.6% in themoderate risk category, and 17.6% in high-
risk category (Table 4).
Finally, we applied themodel to the entire IMMEDIATE Trial dataset
(placebo and GIK arms) and examined the effect of GIK on the different
risk categories by introducing an interaction term. A signiﬁcant interac-
tionwas not found across all the risk categories. In the entire cohort, the
odds of the composite outcome cardiac arrest or in-hospital mortality
related to GIK was 0.45 (CI 0.24, 0.83, p = 0.01). Assuming a constant
odds ratio across the spectrum of calculated risk, the predicted absolute
risk reductionwasmuchmore pronounced for the high-risk group com-
pared to the low-risk group (8.6% vs. 0.8%), with corresponding num-
bers needed to treat (NNT) of 12 and 125 respectively. A constant
odds ratio was used as there was no interaction noted between GIK
and the risk categories.
We studied the clinical proﬁle of the patients in different risk groups
among the IMMEDIATE Trial participants. Table 5 summarizes the dif-
ferences in the study groups. The high-risk group is about four years
older than the entire cohort, has a mean systolic blood pressure on pre-
sentation about 11mmHg lower, with a much higher proportion of pa-
tients having systolic blood pressure below 105 mm Hg. More often
patients in the high-risk group presented within 1 h of ischemic symp-
tom onset, and twice as often had ST elevation on their initial ECG. The
presence of these clinical characteristics in high-risk patients is consis-
tent with our predictive model and with the objective of expediting
treatment of the most at-risk patients.
3.1. Development of a risk scoring system and calculation of IMMEDIATE
Score
For potentially easier use in the ﬁeld by the ﬁrst responder EMS we
developed a simple scoring system based on the rounding to the integer
scores of the coefﬁcients of the four variables in our ﬁnal model. In this
scoring system, henceforth called IMMEDIATE Score, age below60 years
has been assigned a score of 0 and the age group above 60 and less than
or equal to 65 years has been assigned a score of 1, with each 5-year in-
crement increasing the score by 1 to a maximum of 6 for age ≥ 85 years.
Presence of ST elevation in the presenting ECG gives a score of 5, low
systolic blood pressure (b105 mm Hg) at the ﬁrst assessment by the
EMS gives a score of 3 and presentation within 1 h of symptom onset
gives a score of 2. Absence of ST elevation, systolic blood pressureTable 2
Final model (developed on participants treated with placebo).a
Variable Estimate 9
(Intercept) −6.95 −
Age, truncated at 60 and 85b 0.06
ST elevation on out-of-hospital ECG 1.44
Pre-hosp systolic blood pressure b105 mm Hg 0.99
Time from symptom onset to start of treatment (b60 min) 0.68 −
a N = 57 participants treated with placebo and with non-missing data (3 participants exclu
b Age b 60 treated as 60 and age N 85 treated as 85 year.more than 105 mm Hg and presentation later than 1 h from the onset
of symptoms each gives a score of zero in this scale. Thus the range of
the scale may vary from 0 to 16. Table 2 in the Appendix illustrates
the scale with the estimated probabilities of death or cardiac arrest for
each possible score. The scale has excellent calibration (Fig. 4 in the Ap-
pendix) and reasonably maintains the power of discrimination demon-
strated by the predictive model with a C statistic of 0.70 (95% CI: 0.63 to
0.77) compared to the C statistic of 0.75 in the ﬁnalmodel. Although the
C statistic and the corresponding area under the ROC curve (Fig. 5 in the
Appendix) for the scoring system is found to be marginally less than
that of the ﬁnal full model, this difference was not statistically
signiﬁcant.
3.2. Reclassiﬁcation of risk groups based on scoring system
For each model subjects were categorized into 3 risk groups using
two methods, ﬁrst into 3 groups of equal size and second into groups
of equal risk ranges. We assessed the degree of reclassiﬁcation using
predictABLE package in R. No signiﬁcant difference was noted between
the two models by either approach as measured by categorical Net Re-
classiﬁcation Improvement (NRI) or Integrated Discrimination Im-
provement (IDI) (Table 3 in the Appendix) Apparent reclassiﬁcation in
favor of the lower risk categories (Table 4) and its effect on ARR and
NNT (ARR 2.9% and NNT 35 in both moderate and high risk categories)
while an equal number of patients are used to create risk tertiles is pos-
sibly explained by varying weights of different predictors and rounding
to the nearest integer in the simple risk scoringmodel in addition to the
small number of events in different risk groups. Although taking higher
integers to represent the coefﬁcients of themodel may reduce this shift
and maintain rigor in the predictive value of the variables, they may be
difﬁcult to use at the bedside. We encourage a computer based use of
the predictive model to estimate the probability of cardiac arrest or
death. Nevertheless, this simple and easy to use risk scoring system
can be utilized by the EMS to identify patients at higher risk without
any signiﬁcant loss of discrimination power of the original model. This
may expedite important treatment decisions and use of valuable re-
sources,more so in areaswhere access to computer based risk stratiﬁca-
tion is not readily available.
4. Discussion
Based on patients with ACS not receiving GIK in the IMMEDIATE
Trial, we developed a predictive model for the composite outcome of
cardiac arrest or in-hospital mortality, based on four variables: age, sys-
tolic blood pressure, ST elevation on the presenting ECG, and time from5% CI OR 95% CI p value
9.78 −4.24
0.02 0.10 1.06 1.02 1.10 0.002
0.71 2.22 4.22 2.04 9.24 b0.001
0.14 1.78 2.68 1.15 5.96 0.02
0.05 1.40 1.97 0.95 4.06 0.07
ded because of missing blood pressure), C statistic 0.75.
Table 4
Event rates by risk tertiles and treatment groups.
Risk tertiles Observed number of events and rates n (%) Predicted
GIK (n = 408) Placebo (n = 457) OR ARRa NNT
Total
N = 865, missing = 6
17 (4.2) 40 (8.8) 0.45
(0.23, 0.83)
p-value = 0.01
Low
N = 290 (34%)
2 (1.4) 5 (3.4) – 0.8% 125
Moderate
N = 288 (33%)
8 (6.2) 9 (5.6) – 3.3% 30
High
N = 287 (33%)
7 (5.1) 26 (17.6) – 8.6% 12
OR=Odds ratio; ARR= Absolute risk reduction;NNT=Number needed to treat. p value for interaction for test of homogeneity of odds ratio across risk tertiles)=0.12. There is no signiﬁcant
interaction between GIK and risk tertile for the outcome.
a ARR based on a common odds ratio of 0.45 applied to each stratum.
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tive accuracy was good, reﬂected by a C statistic of 0.75, as was its cali-
bration, represented by agreement between the predicted and actual
outcome rates.
When themodel's predictionswere used to create three equal-sized
risk groups, there were noticeable differences between risk tertiles.
These categories showed potential for identifying those patients with
the most to gain from early treatment with GIK. Whereas the overall
odds ratio for GIK's impact on the composite endpoint of cardiac arrest
or mortality in the entire IMMEDIATE Trial cohort was 0.45 (p= 0.01),
high-risk patients appear to have themost potential for beneﬁt. Those in
the high-risk group had an absolute risk reduction by GIK of 8.6%, with a
NNT of 12, versus in the low-risk group having an absolute risk reduc-
tion of 0.8% and a NNT of 125. An apparent increase in the event rate
in the intermediate risk category was possibly due to the statistical
effect of the small number of events in this category.
Treatment of ACS has evolved substantially over the last three de-
cades, resulting in signiﬁcant reductions in morbidity and mortality,
but early mortality remains high [16]. To help address this, there have
been efforts to develop predictive models and risk stratiﬁcation
methods [7,17–21] to support evidence-based treatment that parallel
advances in thrombolysis, antiplatelet therapy, and coronary interven-
tions. To represent the underlying risk of patients with suspected ACS
for the composite outcome of cardiac arrest or mortality, we used data
from the untreated (placebo) group of the IMMEDIATE Trial. Compared
to previous models, ours is simpler, having just four variables that are
clinically straight-forward and easily collected in EMS and ED settings.
Once validated on other data, the model should be applicable to use in
the ﬁeld. In such use, our ﬁndings suggest that it could assist identiﬁca-
tion of the high-risk patients whowould beneﬁt most from administra-
tion of GIK by the EMS and thus could help focus treatment on them.
The overall effect of GIK in the IMMEDIATE Trial on our study out-
come, and conﬁrmed in our analyses, was an odds ratio of 0.45 (p =
0.01). This is independent of other patient-level variables and is very en-
couraging, but in clinical settings, it is understood that there is heteroge-
neity of treatment effect, and being able to select those most likely to
beneﬁt is important [22]. The utility of this is illustrated by theTable 5
Clinical characteristics of participants in different risk tertiles.
Clinical characteristics Overall High
risk
Moderate
risk
Low
risk
Age (years), mean 63.6 67.9 67.6 55.5
Systolic blood pressure
(mm Hg) mean
143 132 144 153
Systolic blood pressure b 105 mm Hg (%) 12% 28% 7% 0%
Presentation ≤ 1 h (%) 37% 63% 16% 28%
ST elevation on presenting ECG (%) 41% 82% 41% 0%difference in potential beneﬁt in the high versus the low risk groups:
8.6% compared to 0.8%, respectively. Thus avoiding cardiac arrest or
mortality should be much more efﬁcient in the high-risk group, for
whom only 12 must be treated to prevent one outcome, versus 125 in
the low-risk group. If validated in an independent group of patients,
our model may help identify the high-risk patients who may be priori-
tized for treatment with GIK, and potentially other important
treatments.
For ease of use in resource limited areas where computer based risk
stratiﬁcation is not easily available we developed a simple integer ver-
sion of the scoring system, the IMMEDIATE Score. By using this 16
point scoring system, the EMS responders can estimate the risk of
death or cardiac arrest for an individual patient in the appropriate
clinical context and tailor clinical decisions accordingly.
The strengths of our study come from data used for the analysis, the
IMMEDIATE Trial, a double-blinded placebo-controlled NIH-sponsored
clinical effectiveness trial that used carefully adjudicated outcomes. An-
other strength is ourmodel's use of few and readily recognizable clinical
predictors (age, SBP, duration from symptom onset, and ST elevation in
ECG on presentation) and its very good predictive performance. Also,
following further validation, it shows promise as being potentially at-
tractive for identifying patients for treatment in varied EMS and ED
settings.4.1. Limitations
There are a number of limitations to this study. The overall
IMMEDIATE Trial with 871 participants had a total of 58 of the compos-
ite events, and for ourmodel, using only the placebo group, we had only
40 events. This is relatively few compared to the candidate number of
variables explored. Also, data were not collected for a few traditional
cardiovascular risk factors such as smoking and family history of prema-
ture coronary artery disease and, from a practical perspective, reliable
collection of these datawas seen as challenging in the acute EMS setting.
It might be of interest to investigate laboratory parameters like CRP, ini-
tial glucose level, and potassium levels, but only the relatively small
IMMEDIATE Trial Biological Mechanism Cohort had these data. More-
over, these tests are not uniformly and promptly available in the EMS
setting and thus were considered unattractive for this predictive
model ultimately aimed at immediate use in EMS and ED care.
Finally, for validation of our ﬁndings and prior to general clinical use,
the predictive model we developed must be tested on other datasets.
This also applies to the ﬁnding of the greater beneﬁt from GIK in the
high-risk group, although such an effect is consistent with other studies
of intervention that ﬁnd more effect with higher risk patients. We en-
courage such testing on analogous data sets, understanding that extant
data on very early treatment with GIK in a placebo-controlled trial are
still hard to ﬁnd.
42 M. Ray et al. / IJC Heart & Vasculature 9 (2015) 37–425. Conclusions
This IMMEDIATE Trial-based predictive model appears to accurately
identify patients with suspected ACS who are at high risk of cardiac ar-
rest or death and who could beneﬁt most from GIK. That the model's
risk factors include earliness of treatment reinforces recent understand-
ing that earlier treatment with GIK is more efﬁcacious. Once the model
has been validated in other datasets and in practice, it could be helpful
in identifying patients most likely to deserve immediate attention and
acute interventions for ACS, including very early out-of-the-hospital
GIK.
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